Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom s Q3 Revenues Slide 11.5 Percent as Losses Decline 29 Percent

NEW YORK, Nov. 1 (GenomeWeb News) - Sequenom today said that third-quarter revenue fell 11.5 percent as net losses narrowed 29 percent.


Total receipts for the three months ended Sept. 30 fell to $4.6 million from $5.2 million in the same quarter last year.


Sequenom spent $2.5 million on R&D in the quarter, compared to $3.5 million in the same quarter last year.


Net losses in the third quarter fell to $6 million from $8.3 million year over year, the company said.


"We are continuing to implement cost-cutting measures announced last month as part of our new business strategy," Harry Stylli, Sequenom's president and CEO, said in a statement.


As of Sept. 30, the company held cash, cash equivalents, short-term investments, and restricted cash totaling $19.7 million.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.